Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) is projected to issue its Q4 2025 results before the market opens on Friday, January 30th. Analysts expect the company to announce earnings of $10.48 per share and revenue of $3.7585 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, January 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the firm posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Up 0.8%

REGN stock opened at $755.51 on Friday. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a market capitalization of $79.40 billion, a price-to-earnings ratio of 18.09, a price-to-earnings-growth ratio of 1.95 and a beta of 0.39. The business’s 50 day moving average price is $754.18 and its two-hundred day moving average price is $641.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Evercore ISI increased their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday. Scotiabank boosted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Finally, BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $794.70.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Banque Transatlantique SA lifted its holdings in shares of Regeneron Pharmaceuticals by 105.4% during the second quarter. Banque Transatlantique SA now owns 304 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 156 shares in the last quarter. MUFG Securities EMEA plc bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $161,000. Papamarkou Wellner Asset Management inc. purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $205,000. Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $226,000. Finally, Larson Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 153.1% during the 3rd quarter. Larson Financial Group LLC now owns 448 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 271 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.